Newsfeeds - Spark Newswire

1 minute read

Travere Therapeutics To Present Abstracts At The Society For Inherited Metabolic Disorders 43rd Annual Meeting And The Genetic Metabolic Dieticians International Conference 2022 April 10-13 And May 4-7

April 6, 4:31 PM

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated

TVTX

1 minute read

Travere Therapeutics Submits New Drug Application For Sparsentan For The Treatment Of IgA Nephropathy

By Benzinga Newsdesk

March 21, 7:02 AM

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the

TVTX

1 minute read

HC Wainwright & Co. Initiates Coverage On Travere Therapeutics with Buy Rating, Announces Price Target of $45

By Benzinga Newsdesk

February 28, 7:48 AM

HC Wainwright & Co. analyst Ed Arce initiates coverage on Travere Therapeutics (NASDAQ:TVTX) with a Buy rating and announces Price Target of $45.

TVTX

1 minute read

Earnings

Travere Therapeutics: Q4 Earnings Insights

By Benzinga Insights

February 24, 5:49 PM

Travere Therapeutics (NASDAQ:TVTX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

TVTX

1 minute read

Earnings

Travere Therapeutics’s Earnings: A Preview

By Benzinga Insights

February 23, 12:32 PM

Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts estimate that Travere Therapeutics will report an earnings per share (EPS) of $-0.72.

TVTX

4 minute read

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

By Shanthi Rexaline

February 20, 9:06 AM

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

ABCL

2 minute read

Travere Therapeutics 8-K Shows Co. Commercial Supply Deal With Catalent Pharma Solutions For Services Related To Processing, Packaging Of Sparsentan Tablets, No Terms Disclosed

By Benzinga Newsdesk

December 22, 5:11 PM

On December 21, 2021, Travere Therapeutics, Inc. (the “Company”) entered into a Commercial Supply Agreement (the “Supply Agreement”) with Catalent Pharma Solutions, LLC (“Catalent”),

TVTX

1 minute read

SVB Leerink Maintains Outperform on Travere Therapeutics, Raises Price Target to $42

By Benzinga Newsdesk

December 16, 5:34 AM

SVB Leerink analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $37 to $42.

TVTX

1 minute read

Travere Posts Topline Data For Pegtibatinase In patients With Rare Metabolic Disorder

By Vandana Singh

December 15, 11:25 AM

Travere Therapeutics Inc (NASDAQ: TVTX)

TVTX

1 minute read

CORRECTION: Travere Therapeutics Q3 EPS $(0.13) Beats $(0.54) Estimate, Sales $68.22M Beat $60.93M Estimate

By Benzinga Newsdesk

October 28, 6:01 PM

Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.54) by 75.93 percent. This is a 18.18 percent decrease over losses of $(0.11) per share

TVTX